Skip to main content

Table 1 Clinical and laboratory data of NHR-NICE and HR-NICE group

From: Early risk assessment of circulating endothelial progenitor cells and plasma stromal cell-derived factor-1 for nondisabling ischemic cerebrovascular events

 

NHR-NICE(70)

HR-NICE(83)

P

Time to sampling(h)

10.69 ± 5.00

9.98 ± 4.69

0.370

Age (year)

56.50 ± 8.16

62.63 ± 5.29

<0.01

Male n (%)

40(57.14%)

45(54.22%)

0.719

Hypertension n (%)

15(21.43%)

46(55.42%)

<0.01

Diabetes n (%)

7(10.00%)

33(39.76%)

<0.01

Smoking n (%)

28(40.00%)

24(28.92%)

0.149

BMI24 n (%)

27(38.57%)

36(43.37)

0.548

TG (mmol/L)

2.14 ± 0.59

2.44 ± 0.59

<0.01

TC (mmol/L)

5.32 ± 0.74

5.67 ± 0.74

<0.01

LDL (mmol/L)

3.42 ± 0.60

3.64 ± 0.70

0.018

HCY umol/L

14.48 ± 4.70

14.30 ± 5.79

0.514

EPCs(EPCs/PMNC,‱)

5.75 ± 0.97

4.09 ± 0.77

<0.01

SDF-1 (pg/ml)

470.30 ± 20.14

755.12 ± 29.67

<0.01

VEGF (pg/ml)

70.97 ± 3.27

83.28 ± 2.36

<0.01

  1. Time to sampling: time from onset to collect blood sample;BMI Body Mass Index, TG Triglyceride, TC Total Cholesterol, LDL Low Density Lipoprotein, EPCs Endothelial Progenitor Cells, SDF-1 Stromal Cell-Derived Factor-1, VEGF, Vascular Endothelial Growth Factor